ArticleAntibiotics (Basel, Switzerland)2022
Carbapenem Combinations for Infections Caused by Carbapenemase-Producing
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Prevalence of meropenem-resistant Pseudomonas Aeruginosa in Ethiopia: a systematic review and meta‑analysis.Antimicrobial resistance and infection control · 2024Pooled it
- Targeting the outer membrane porin OprF restores carbapenem efficacy during experimental sepsis caused by NDM-1-producing Pseudomonas aeruginosa.Scientific reports · 2026Article
- High-riskHeliyon · 2025Article
- Mitomycin C as an Anti-Persister Strategy againstAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic Resistance in Bacterial Pathogens.Antibiotics (Basel, Switzerland) · 2023Article
- The CARBA-MAP study: national mapping of carbapenemases in Spain (2014-2018).Frontiers in microbiology · 2023Article
- Novel evidence on sepsis-inducing pathogens: from laboratory to bedside.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
In the context of difficult-to-treat carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.